RU2496519C2 - Способ получения препарата, содержащего вирусные антигены, и применение препарата - Google Patents

Способ получения препарата, содержащего вирусные антигены, и применение препарата Download PDF

Info

Publication number
RU2496519C2
RU2496519C2 RU2010111747/10A RU2010111747A RU2496519C2 RU 2496519 C2 RU2496519 C2 RU 2496519C2 RU 2010111747/10 A RU2010111747/10 A RU 2010111747/10A RU 2010111747 A RU2010111747 A RU 2010111747A RU 2496519 C2 RU2496519 C2 RU 2496519C2
Authority
RU
Russia
Prior art keywords
virus
specified
cells
inactivation
viral antigens
Prior art date
Application number
RU2010111747/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2010111747A (ru
Inventor
Отфрид Кистнер
Криста ТАУЭР
Ноэль Барретт
Вольфганг Мундт
Original Assignee
Бакстер Интернэшнл Инк.
Бакстер Хелткэр С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бакстер Интернэшнл Инк., Бакстер Хелткэр С.А. filed Critical Бакстер Интернэшнл Инк.
Publication of RU2010111747A publication Critical patent/RU2010111747A/ru
Application granted granted Critical
Publication of RU2496519C2 publication Critical patent/RU2496519C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2010111747/10A 2007-08-28 2008-08-28 Способ получения препарата, содержащего вирусные антигены, и применение препарата RU2496519C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96672407P 2007-08-28 2007-08-28
US60/966,724 2007-08-28
PCT/US2008/074559 WO2009029695A1 (en) 2007-08-28 2008-08-28 Method for producing viral vaccines

Publications (2)

Publication Number Publication Date
RU2010111747A RU2010111747A (ru) 2011-10-10
RU2496519C2 true RU2496519C2 (ru) 2013-10-27

Family

ID=39947984

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010111747/10A RU2496519C2 (ru) 2007-08-28 2008-08-28 Способ получения препарата, содержащего вирусные антигены, и применение препарата

Country Status (16)

Country Link
US (2) US8497112B2 (https=)
EP (1) EP2192917B1 (https=)
JP (1) JP5535910B2 (https=)
KR (1) KR101760844B1 (https=)
CN (1) CN101790381B (https=)
AU (1) AU2008293513B2 (https=)
BR (1) BRPI0816130A2 (https=)
CA (1) CA2696090C (https=)
ES (1) ES2459166T3 (https=)
HR (1) HRP20140375T1 (https=)
IL (1) IL203869A (https=)
PL (1) PL2192917T3 (https=)
RU (1) RU2496519C2 (https=)
SG (1) SG10201404101RA (https=)
SI (1) SI2192917T1 (https=)
WO (1) WO2009029695A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052061A2 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
EA201070066A1 (ru) * 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
WO2010092479A2 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with reduced amounts of squalene
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
GB0918830D0 (en) * 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
US20130039943A1 (en) * 2010-05-03 2013-02-14 Bruno Rene Andre Novel method
MX342138B (es) 2010-07-06 2016-09-14 Variation Biotechnologies Inc Composiciones y metodos para el tratamiento de influenza.
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
CA2862871C (en) 2011-01-13 2020-09-22 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
CA2841604C (en) * 2011-07-20 2020-01-21 Abbott Biologicals B.V. Process for producing viral antigen and vaccines
ES2726975T3 (es) * 2011-07-27 2019-10-11 Flash Therapeutics Método para la producción de partículas retrovíricas útiles para transducir células eucariotas
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
WO2015059065A1 (en) * 2013-10-22 2015-04-30 Roche Diagnostics Gmbh Methods for measuring cell-free virus particles from dried blood spots
FR3025107B1 (fr) * 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
CN111979120B (zh) * 2019-05-23 2022-09-27 比欧联科供应链管理(北京)有限公司 一种狂犬疫苗核酸消化去除装置及实验方法
RU2754398C1 (ru) * 2020-06-25 2021-09-01 Общество с ограниченной ответственностью «ФОРТ» Способ получения четырехвалентной вакцины для профилактики гриппа

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1498261A (en) * 1974-01-14 1978-01-18 Sandoz Ltd Influenza vaccines
EP0105788A1 (fr) * 1982-09-28 1984-04-18 "DEGREMONT" Société dite: Procédé et appareil de traitement anaérobie d'eaux résiduaires dans un filtre à remplissage de matériau granulaire
EP0172433A2 (en) * 1984-08-02 1986-02-26 Tektronix, Inc. Display method and apparatus employing cursor panning
EP0514199A2 (en) * 1991-05-17 1992-11-19 Retroscreen Limited Vaccines and methods for their production
RU2082433C1 (ru) * 1992-07-13 1997-06-27 Николай Владимирович Костючек Способ вакцинопрофилактики гриппа
RU2195959C1 (ru) * 2001-11-02 2003-01-10 Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных Инактивированная вакцина против синдрома гидроперикардита кур
RU2261111C1 (ru) * 2004-04-08 2005-09-27 Сергеев Виталий Александрович Инактивированная вакцина против вирусных пневмогастроэнтеритов крупного рогатого скота и телят и способ профилактики вирусных пневмогастроэнтеритов

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2475572A1 (fr) 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
CN1223589A (zh) * 1996-05-06 1999-07-21 美国拜尔公司 包含鹦鹉热衣原体的猫疫苗及其制备方法
AT405939B (de) * 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
US6841374B1 (en) * 1998-10-05 2005-01-11 Research Foundation For Microbial Diseases Of Osaka University Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same
CA2355270A1 (en) 1998-12-17 2000-06-22 Aventis Pasteur Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
KR20030046395A (ko) 2000-07-28 2003-06-12 인스파이어 파마슈티컬스 인코퍼레이티드 인돌 유도체를 사용하여 안압을 감소시키는 방법
GB0024089D0 (en) * 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US8703467B2 (en) * 2004-05-27 2014-04-22 Baxter International Inc. Inactivation of a pathogen in a sample by a treatment with formalin and UV light
CN1647822A (zh) * 2005-02-06 2005-08-03 北京生物制品研究所 脊髓灰质炎灭活疫苗及其制备方法
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1498261A (en) * 1974-01-14 1978-01-18 Sandoz Ltd Influenza vaccines
EP0105788A1 (fr) * 1982-09-28 1984-04-18 "DEGREMONT" Société dite: Procédé et appareil de traitement anaérobie d'eaux résiduaires dans un filtre à remplissage de matériau granulaire
EP0172433A2 (en) * 1984-08-02 1986-02-26 Tektronix, Inc. Display method and apparatus employing cursor panning
EP0514199A2 (en) * 1991-05-17 1992-11-19 Retroscreen Limited Vaccines and methods for their production
RU2082433C1 (ru) * 1992-07-13 1997-06-27 Николай Владимирович Костючек Способ вакцинопрофилактики гриппа
RU2195959C1 (ru) * 2001-11-02 2003-01-10 Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных Инактивированная вакцина против синдрома гидроперикардита кур
RU2261111C1 (ru) * 2004-04-08 2005-09-27 Сергеев Виталий Александрович Инактивированная вакцина против вирусных пневмогастроэнтеритов крупного рогатого скота и телят и способ профилактики вирусных пневмогастроэнтеритов

Also Published As

Publication number Publication date
ES2459166T3 (es) 2014-05-08
CA2696090A1 (en) 2009-03-05
HRP20140375T1 (hr) 2014-06-20
BRPI0816130A2 (pt) 2015-02-24
KR20100075865A (ko) 2010-07-05
US8497112B2 (en) 2013-07-30
KR101760844B1 (ko) 2017-07-24
CN101790381B (zh) 2014-08-27
SI2192917T1 (sl) 2014-05-30
WO2009029695A1 (en) 2009-03-05
AU2008293513A1 (en) 2009-03-05
JP2010537641A (ja) 2010-12-09
EP2192917B1 (en) 2014-01-29
HK1143328A1 (en) 2010-12-31
SG10201404101RA (en) 2014-09-26
IL203869A (en) 2016-05-31
RU2010111747A (ru) 2011-10-10
PL2192917T3 (pl) 2014-06-30
AU2008293513B2 (en) 2013-11-21
CN101790381A (zh) 2010-07-28
CA2696090C (en) 2017-06-13
US20130287811A1 (en) 2013-10-31
US20090060950A1 (en) 2009-03-05
EP2192917A1 (en) 2010-06-09
JP5535910B2 (ja) 2014-07-02

Similar Documents

Publication Publication Date Title
RU2496519C2 (ru) Способ получения препарата, содержащего вирусные антигены, и применение препарата
US11466257B2 (en) Cell-derived viral vaccines with low levels of residual cell DNA
RU2197264C2 (ru) Способ получения поверхностных антигенных белков из вирусов гриппа, противогриппозная вакцина
RU2565827C2 (ru) Способ получения вирусного антигена и вакцин
JP2012507272A (ja) 新規な方法
US20120058145A1 (en) Method for producing virus from cell culture involving homogenization
AU2004249802B2 (en) Improvements in virus production
KR20110099810A (ko) 포르말린 및 ｕｖ광으로의 처리에 의한 샘플 중 병원균의 불활성화
JP5843615B2 (ja) 密度勾配超遠心分離によるウイルスまたはウイルス抗原の精製
JP6200805B2 (ja) 新規な方法
WO2022051327A1 (en) Hemagglutinin modifications for improved influenza vaccine production
EP3234113B1 (en) A method for a large scale virus purification
HK1143328B (en) Method for producing viral vaccines
RU2604414C2 (ru) Живая вакцина для профилактики гриппа и способ ее получения
KR20070030852A (ko) 포르말린 및 ｕｖ광으로의 처리에 의한 샘플 중 병원균의불활성화
HK1129837B (en) Cell-derived viral vaccines with low levels of residual cell dna

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170829